Sacituzumab Tirumotecan (MK-2870) in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-Based Combination Therapy

NCT07720258 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

27

Enrollment

OTHER_GOV

Sponsor class

Conditions

Advanced Small Bowel Adenocarcinoma

Interventions

DRUG: Sacituzumab tirumotecan

Sponsor

National Cancer Center, Japan